Insmed (INSM) has been drawing attention from investors after recent trading activity, as they weigh the company’s rare disease portfolio, including ARIKAYCE and late stage programs like brensocatib and treprostinil palmitil inhalation powder.

Insmed’s share price has retreated from recent highs, with the latest close at US$97.46 and the 90 day share price return down 32.29%, even though the 3 year total shareholder return is very large at about 4x. Recent trading swings appear to reflect shifting views on the risk and potential of its rare disease pipeline rather than any single headline event.

If you are following Insmed because of its late stage pipeline, it can also be useful to size up other healthcare AI opportunities using our screener for 39 healthcare AI stocks

With Insmed’s share price pulling back and the stock trading at what some might view as a steep discount to certain intrinsic estimates, the key question is whether this is a genuine opportunity or if the market already reflects the company’s future growth.

Most Popular Narrative: 51.3% Undervalued

At a last close of US$97.46, the most followed narrative pegs Insmed’s fair value at US$200.00, creating a wide gap that investors are actively debating.

The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3. The upcoming Phase II data for TPIP in PAH by mid-2025 and brensocatib in CRS without nasal polyps by the end of 2025 are key clinical milestones that could enhance future revenue streams if positive.

Want to see how this story is built? Analysts are stacking aggressive revenue expansion, margin shift and a rich future earnings multiple into one valuation blueprint.

Result: Fair Value of $200.00 (UNDERVALUED)

However, this hinges on timely approvals and payer support. Any FDA delays or tougher reimbursement terms could quickly challenge the upbeat growth narrative investors are debating.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Multiples Paint a Tougher Picture

The popular undervalued story leans heavily on future cash flows, but the current P/S of 25.8x tells a tougher story. It sits well above the US Biotechs average of 10.3x and above a fair ratio of 18.8x, which points to meaningful valuation risk if growth stumbles or is pushed out.

Before leaning too hard on long term forecasts, it can help to test whether that P/S gap matches your own expectations for Insmed’s pipeline and commercial execution, or whether it leaves too little room for error.

Next Steps

If this mix of optimism and concern feels familiar, act while the debate is still live by reviewing the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If Insmed is on your watchlist, do not stop there. Widen your search now or you risk missing other stocks that might better fit your goals.

• Spot potential bargains early by scanning the 47 high quality undervalued stocks that combine quality fundamentals with pricing that some investors may find appealing.
• Build a sturdier core for your portfolio by checking the solid balance sheet and fundamentals stocks screener (48 results) that focus on financial strength and resilience.
• Get ahead of the crowd by reviewing the screener containing 20 high quality undiscovered gems that highlight lesser known companies with solid underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.